|
关于:
|
The European Medicines Firm review of entrectinib for the treatment adult or paediatric people together with strong tumours who've a neurotrophic tyrosine receptor kinase gene fusions and mature individuals with non-small-cell lung cancer harbouring ROS1 rearrangements.
|
